199 related articles for article (PubMed ID: 37195776)
21. Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes.
Hasserjian RP; Buckstein R; Patnaik MM
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():328-350. PubMed ID: 34010050
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Myeloid Lineages and the Immune Microenvironment in Myelodysplastic Syndromes: Novel and Evolving Therapeutic Strategies.
Chung C
Ann Pharmacother; 2022 Apr; 56(4):475-487. PubMed ID: 34330162
[TBL] [Abstract][Full Text] [Related]
23. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
24. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Stahl M; Zeidan AM
Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
[TBL] [Abstract][Full Text] [Related]
27. [Current treatment strategies for myelodysplastic syndromes].
Suzuki T
Rinsho Ketsueki; 2015 Oct; 56(10):1985-95. PubMed ID: 26458437
[TBL] [Abstract][Full Text] [Related]
28. Established and novel agents for myelodysplastic syndromes.
Sekeres MA; Gerds AT
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):82-9. PubMed ID: 25696839
[TBL] [Abstract][Full Text] [Related]
29. [Identification of myelodysplastic syndromes patients].
Santini V
Recenti Prog Med; 2014 Mar; 105(3):127-31. PubMed ID: 24675456
[TBL] [Abstract][Full Text] [Related]
30. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.
Steensma DP; Fenaux P; Van Eygen K; Raza A; Santini V; Germing U; Font P; Diez-Campelo M; Thepot S; Vellenga E; Patnaik MM; Jang JH; Varsos H; Bussolari J; Rose E; Sherman L; Sun L; Wan Y; Dougherty S; Huang F; Feller F; Rizo A; Platzbecker U
J Clin Oncol; 2021 Jan; 39(1):48-56. PubMed ID: 33108243
[TBL] [Abstract][Full Text] [Related]
31. Management of patients with lower-risk myelodysplastic syndromes.
Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
[TBL] [Abstract][Full Text] [Related]
32. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP; Zeidan AM
Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
[TBL] [Abstract][Full Text] [Related]
33. Overview of the Management of Higher-Risk Myelodysplastic Syndromes.
Singh A; Carraway HE
Cancer J; 2023 May-Jun 01; 29(3):160-167. PubMed ID: 37195772
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
Scalzulli E; Pepe S; Colafigli G; Breccia M
Blood Rev; 2021 Jan; 45():100689. PubMed ID: 32253020
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
Montalban-Bravo G; Garcia-Manero G
Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: The Current Landscape and Future Directions.
Sabile J; Pavletic S; Migdady Y
Cancer J; 2023 May-Jun 01; 29(3):179-187. PubMed ID: 37195774
[TBL] [Abstract][Full Text] [Related]
37. New investigational combinations for higher-risk MDS.
Koenig KL; Borate U
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):368-374. PubMed ID: 36485141
[TBL] [Abstract][Full Text] [Related]
38. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.
Patel SS; Sekeres MA; Nazha A
Leuk Lymphoma; 2017 Nov; 58(11):2532-2539. PubMed ID: 28351181
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
40. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]